Scientists review GLP-1 drugs' potential to reduce Alzheimer's-related protein buildup
Updated
Updated · Earth.com · Apr 25
Scientists review GLP-1 drugs' potential to reduce Alzheimer's-related protein buildup
10 articles · Updated · Earth.com · Apr 25
The review, led by Dr. Simon Cork at Anglia Ruskin University, analyzed 30 lab studies and two clinical trials on drugs like Ozempic, Wegovy, liraglutide, and semaglutide.
Most animal studies showed these drugs reduce beta-amyloid and tau proteins, though results varied by drug and sex. Human trials found biological changes but no clear cognitive improvement yet.
Researchers suggest GLP-1 drugs may work best before Alzheimer's symptoms appear, highlighting the need for larger, early-stage clinical trials to confirm preventive effects in at-risk individuals.
Why did a major trial for an Ozempic-like drug fail for Alzheimer's treatment?
If your genes affect how Ozempic works, could they also predict its impact on your brain?
With conflicting results, should doctors ever prescribe weight-loss drugs for brain health?
Is the failure of recent Alzheimer's drugs pushing us toward metabolic solutions?
Can we afford to give millions of healthy people expensive drugs to prevent dementia?
Why Semaglutide Failed in Alzheimer's: Biomarker Gains Without Clinical Benefit in Large Phase 3 EVOKE Studies
Overview
The 2026 EVOKE trials revealed that semaglutide failed to slow Alzheimer's progression despite improving key disease biomarkers, leading Novo Nordisk to halt its Alzheimer's development. This disconnect is partly explained by semaglutide's minimal ability to cross the blood-brain barrier, causing its effects to be mainly indirect. In contrast, dulaglutide shows higher brain penetration and potential for direct neuroprotection but lacks large clinical trials. Real-world data suggest GLP-1 drugs, including semaglutide, reduce Alzheimer's risk in diabetes patients, shifting focus toward prevention in high-risk groups. Future efforts emphasize combination therapies and next-generation GLP-1 drugs with better brain access to overcome current limitations.